Fennec Pharmaceuticals Valuation
| FENC Stock | USD 8.78 0.19 2.12% |
At this time, the firm appears to be undervalued. Fennec Pharmaceuticals shows a prevailing Real Value of $10.28 per share. The current price of the firm is $8.78. Our model computes the value of Fennec Pharmaceuticals from reviewing the firm fundamentals such as Profit Margin of (0.18) %, current valuation of 260.75 M, and Shares Outstanding of 34.15 M as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Fennec Pharmaceuticals' valuation include:
Price Book 57.9258 | Enterprise Value | Enterprise Value Ebitda 20.2719 | Price Sales 7.6425 | Forward PE 13.0719 |
Undervalued
Today
Please note that Fennec Pharmaceuticals' price fluctuation is not too volatile at this time. Calculation of the real value of Fennec Pharmaceuticals is based on 3 months time horizon. Increasing Fennec Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Fennec Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Fennec Stock. However, Fennec Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 8.78 | Real 10.28 | Target 15.29 | Hype 8.8 | Naive 9.18 |
The real value of Fennec Stock, also known as its intrinsic value, is the underlying worth of Fennec Pharmaceuticals Company, which is reflected in its stock price. It is based on Fennec Pharmaceuticals' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Fennec Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Fennec Pharmaceuticals helps investors to forecast how Fennec stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Fennec Pharmaceuticals more accurately as focusing exclusively on Fennec Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Fennec Pharmaceuticals' intrinsic value based on its ongoing forecasts of Fennec Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Fennec Pharmaceuticals' closest peers. If more than one evaluation category is relevant for Fennec Pharmaceuticals we suggest using both methods to arrive at a better estimate.
Fennec Pharmaceuticals Cash |
|
Fennec Pharmaceuticals Total Value Analysis
Fennec Pharmaceuticals is currently estimated to have valuation of 260.75 M with market capitalization of 296.45 M, debt of 19.34 M, and cash on hands of 14.91 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Fennec Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
260.75 M | 296.45 M | 19.34 M | 14.91 M |
Fennec Pharmaceuticals Investor Information
About 13.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.26. Fennec Pharmaceuticals had not issued any dividends in recent years. The entity had 1:3 split on the 9th of September 2014. Based on the key indicators related to Fennec Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Fennec Pharmaceuticals may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.Fennec Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Fennec Pharmaceuticals has an asset utilization ratio of 105.77 percent. This indicates that the Company is making $1.06 for each dollar of assets. An increasing asset utilization means that Fennec Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Fennec Pharmaceuticals Profitability Analysis
Based on Fennec Pharmaceuticals' profitability indicators, Fennec Pharmaceuticals' profitability may be sliding down. It has an above-average odds of reporting lower numbers next quarter. Profitability indicators assess Fennec Pharmaceuticals' ability to earn profits and add value for shareholders.Net Loss | First Reported 2000-06-30 | Previous Quarter -3.2 M | Current Value -638 K | Quarterly Volatility 2.9 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 1.02 | 1.07 |
|
|
For Fennec Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Fennec Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Fennec Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Fennec Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Fennec Pharmaceuticals over time as well as its relative position and ranking within its peers.
Fennec Pharmaceuticals Earnings per Share Projection vs Actual
The next projected EPS of Fennec Pharmaceuticals is estimated to be -0.028125 with future projections ranging from a low of -0.03 to a high of -0.025. Fennec Pharmaceuticals' most recent 12-month trailing earnings per share (EPS TTM) is at -0.26. Please be aware that the consensus of earnings estimates for Fennec Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Fennec Pharmaceuticals Earnings Estimation Breakdown
The calculation of Fennec Pharmaceuticals' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Fennec Pharmaceuticals is estimated to be -0.028125 with the future projection ranging from a low of -0.03 to a high of -0.025. Please be aware that this consensus of annual earnings estimates for Fennec Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.03 Lowest | Expected EPS | -0.03 Highest |
Fennec Pharmaceuticals Earnings Projection Consensus
Suppose the current estimates of Fennec Pharmaceuticals' value are higher than the current market price of the Fennec Pharmaceuticals stock. In this case, investors may conclude that Fennec Pharmaceuticals is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Fennec Pharmaceuticals' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 7 | 27.97% | -0.02 | -0.028125 | -0.26 |
Fennec Pharmaceuticals Ownership Allocation
Fennec Pharmaceuticals holds a total of 34.15 Million outstanding shares. Over half of Fennec Pharmaceuticals' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that obtain positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Fennec Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 47.54 M. Net Loss for the year was (436 K) with profit before overhead, payroll, taxes, and interest of 36.12 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Fennec Pharmaceuticals' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Fennec Pharmaceuticals and how it compares across the competition.
About Fennec Pharmaceuticals Valuation
The stock valuation mechanism determines Fennec Pharmaceuticals' current worth on a weekly basis. Our valuation model uses a comparative analysis of Fennec Pharmaceuticals. We calculate exposure to Fennec Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Fennec Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 51 M | 53.6 M | |
| Operating Profit Margin | 0.05 | 0.05 | |
| Net Loss | (0.01) | (0.01) | |
| Gross Profit Margin | 1.07 | 1.02 |
Fennec Pharmaceuticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 27.3 M | |
| Forward Price Earnings | 13.0719 |
Fennec Pharmaceuticals Current Valuation Indicators
Valuation refers to the process of determining the present value of Fennec Pharmaceuticals and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Fennec we look at many different elements of the entity such as Fennec's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Fennec Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Fennec Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Fennec Pharmaceuticals' worth.Complementary Tools for Fennec Stock analysis
When running Fennec Pharmaceuticals' price analysis, check to measure Fennec Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fennec Pharmaceuticals is operating at the current time. Most of Fennec Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Fennec Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fennec Pharmaceuticals' price. Additionally, you may evaluate how the addition of Fennec Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Stocks Directory Find actively traded stocks across global markets | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |